Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS	23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:43:31 ON 13 FEB 2007

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:43:38 ON 13 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9
DICTIONARY FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s methyl caffeate
      17332230 METHYL
            97 METHYLS
      17332230 METHYL
                  (METHYL OR METHYLS)
           540 CAFFEATE
L1           4 METHYL CAFFEATE
                  (METHYL(W)CAFFEATE)

=> d 4

L1   ANSWER 4 OF 4  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   1782-53-2  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2-Propenoic acid, 3-(3,4-dioxo-1,5-cyclohexadien-1-yl)-, methyl ester
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1,5-Cyclohexadiene-1-acrylic acid, 3,4-dioxo-, methyl ester (7CI, 8CI)
OTHER NAMES:
CN   Caffeoquinone methyl ester
CN   Methyl caffeate quinone
MF   C10 H8 O4
LC   STN Files:   BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER
         (*File contains numerically searchable property data)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 1-3

L1 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 873918-36-6 REGISTRY
ED Entered STN: 10 Feb 2006
CN 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (2,2-Dimethyl-1,3-dioxolan-4-yl)methyl caffeate
MF C15 H18 O6
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 58058-70-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Propenoic acid, 3-[3,4-dihydroxy-5-(phenylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5'-Phenylsulfonyl methyl caffeate
MF C16 H14 O6 S
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 3843-74-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cinnamic acid, 3,4-dihydroxy-, methyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN Caffeic acid methyl ester
CN Methyl 3,4-dihydroxycinnamate
CN Methyl caffeate
CN Methyl caffeoate
MF C10 H10 O4
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

231 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
233 REFERENCES IN FILE CAPLUS (1907 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s caffeoylquinate
L2 7 CAFFEOYLQUINATE

=> d 5-7

L2 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 143051-73-4 REGISTRY
ED Entered STN: 19 Aug 1992
CN Cyclohexanecarboxylic acid, 3,4-bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-

propenyl]oxy]-1,5-dihydroxy-, ethyl ester, [1S-[1α,3β(E),4α(E),5α]]- (9CI) (CA INDEX NAME)

OTHER NAMES:
CN Ethyl 3,4-dicaffeoylquinate
FS STEREOSEARCH
MF C27 H28 O12
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 123372-74-7 REGISTRY
ED Entered STN: 27 Oct 1989
CN Cyclohexanecarboxylic acid, 4-[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,3,5-trihydroxy-, methyl ester, (1α,3R,4α,5R)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Methyl 4-O-caffeoylquinate
FS STEREOSEARCH
MF C17 H20 O9
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
RN 29708-87-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, methyl ester, (1S,3R,4R,5R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Chlorogenic acid, methyl ester (8CI)
CN Cyclohexanecarboxylic acid, 3-[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-1,4,5-trihydroxy-, methyl ester, [1S-(1α,3β,4α,5α)]-
OTHER NAMES:
CN Methyl 5-O-caffeoylquinate
CN Methyl chlorogenate
FS STEREOSEARCH
MF C17 H20 O9
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, IPA, NAPRALERT, TOXCENTER
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Connection closed by remote host

L1 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 53902-12-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN 2-(3,4-Dimethoxycinnamoylamino)benzoic acid
CN MK 341
CN N 5'
CN N-(3',4'-Dimethoxycinnamoyl)anthranilic acid
CN N-(3,4-Dimethoxycinnamoyl)anthranilic acid
CN Rizaben
CN Tranilast
CN Tranpro
MF C18 H17 N O5
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

548 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
548 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L9 ANSWER 17 OF 190 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:900158 CAPLUS
DOCUMENT NUMBER: 135:55773
TITLE: Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat
AUTHOR(S): Pinto, Yigal M.; Pinto-Sietsma, Sara-Joan; Philipp, Tobias; Engler, Sonja; Kossmehl, Peter; Hocher, Berthold; Marquardt, Heike; Sethmann, Svenja; Lauster, Roland; Merker, Hans-Joachim; Paul, Martin
CORPORATE SOURCE: Department of Clinical Pharmacology and Toxicology Benjamin Franklin Medical Center, Freie Universitat Berlin, Berlin, 14195, Germany
SOURCE: Hypertension (2000), 36(5), 747-754
CODEN: HPRTDN; ISSN: 0194-911X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Angiotensin II recruits transforming growth factor β1 (TGFβ1) and is related to left ventricular fibrosis. However, it is unclear whether chronic in vivo reduction in left ventricular TGFβ1 expression blunts fibrosis and improves outcome in angiotensin II-dependent hypertension. Four-week-old male hypertensive TGR(mRen2)27 (Ren2) rats received either normal food, low-dose losartan (0.5 mg/kg/d), or tranilast (a nonspecific TGFβ inhibitor; 400 mg/kg/d) for 12 wk and were compared with Sprague-Dawley control rats. The effect of tranilast on survival was evaluated in 34 addnl. untreated homozygous Ren2 rats. Tranilast or low-dose losartan did not lower blood pressure. However, the increase in left ventricular weight (Ren2 vs. SD 3.1 vs. 2.1 mg/g) was significantly blunted by both tranilast (2.7) and losartan (2.7). Both drugs prevented the increase in left ventricular TGFβ1 mRNA and fibronectin mRNA and blunted the increase in hydroxyproline content and the increase in perivascular fibrosis. The perivascular fibrosis score correlated significantly with the level of expression of TGFβ1 ($r = 0.62$). In situ hybridization demonstrated increases in TGFβ1 mRNA, predominantly in perivascular and nonmyocyte areas. Both drugs did not prevent the decrease in systolic or diastolic dP/dt, but tranilast significantly improved the survival of untreated Ren2 rats. In conclusion, TGFβ1 mRNA expression is increased predominantly in nonmyocyte regions in the hypertrophied left ventricle in this angiotensin II-dependent model of hypertension. This increase is probably due to high angiotensin II levels rather than to hypertension. This is the first study to suggest that chronic inhibition of TGFβ1 expression attenuates left ventricular hypertrophy and fibrosis, even without lowering blood pressure.
IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF-β1 mRNA reduction in left ventricle attenuates left ventricular fibrosis and improves survival without lowering blood pressure in hypertensive TGR(mRen2)27 rats)
RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 190 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:659729 CAPLUS
DOCUMENT NUMBER: 131:295291
TITLE: Effect of tranilast on the retinal vessels in the hypertensive rat
AUTHOR(S): Honda, Yukie; Aoike, Chiaki
CORPORATE SOURCE: Second Dep. Ophthalmol., Toho Univ. Sch. Med., 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-0044, Japan
SOURCE: Atarashii Ganka (1999), 16(9), 1291-1294
CODEN: ATGAEX; ISSN: 0910-1810
PUBLISHER: Medikaru Ai Shuppan
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB We investigated the effect of tranilast on the retinal vessels in spontaneously hypertensive rats (SHR). Salt loading stroke-prone SHR (SHR-sp) were assigned to either the treated group (dosed with tranilast) or the untreated group. After treatment, computer imaging anal. showed retinal vessel thickness to be significantly inhibited in the treatment group after 8 wk of treatment ($p = 0.008$). This result suggests that tranilast may have an inhibitory effect on early stage hypertensive retinopathy.

IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of tranilast on retinal vessels in hypertensive rat)

RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 190 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:698915 CAPLUS
DOCUMENT NUMBER: 130:60839
TITLE: Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart
AUTHOR(S): Umemura, Kazuo; Kikuchi, Shinji; Suzuki, Yasuhiro; Nakashima, Mitsuyoshi
CORPORATE SOURCE: Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, 431 - 31, Japan
SOURCE: Japanese Journal of Pharmacology (1998), 78(2), 161-167
CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tranilast, N-(3,4-dimethoxycinnamoyl)anthranilic acid, a widely used antiallergy drug in Japan, has been shown to inhibit transforming growth factor-β1 release from fibroblasts and reduce collagen synthesis in keloid cells. In the present study, we have investigated the effect of this drug on cardiac hypertrophy in spontaneously hypertensive rats (SHR), with a focus on the cardiac collagen matrix, which is associated with myocardial stiffness. Twenty-four-week-old SHRs and Wistar Kyoto rats (WKYs) were administered tranilast (300 mg/kg) orally once a day for 4 wk. This treatment significantly suppressed increases in left ventricular collagen concentration ($P<0.05$) and the left ventricular weight/body wts. ratios ($P<0.05$) in SHRs, and tranilast was ineffective on collagen concentration and ventricular weight/body wts. ratios in WKYs. Tranilast did not affect systolic or diastolic blood pressure, end-diastolic left ventricular pressure and heart rate in both SHRs and WKYs, and the agent did not change pos. dp/dt or cardiac output in SHRs. The pressure-volume relation curve was shifted to the left by the drug; the slope (k) of the logarithm of the pressure-volume relation curve was significantly increased ($P<0.05$) in SHRs. It is concluded that the suppression of increases in cardiac collagen and left ventricular mass by tranilast results in a corresponding prevention of cardiac stiffness as studied in the SHR.

IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart)

RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:152482 CAPLUS
DOCUMENT NUMBER: 134:157568
TITLE: Agent inhibiting hypertensive arteriolar disorder
INVENTOR(S): Iwaki, Yoichi; Kusama, Hiroshi; Tsuji, Atsutoshi
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013911	A1	20010301	WO 2000-JP4528	20000707 <--
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: JP 1999-233008 A 19990819

AB This document discloses an agent inhibiting diseases concerning hypertensive arteriolar disorder (cerebral stroke, vascular dementia, hypertensive eyeground, hypertensive retinopathy, etc.) containing as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (tranilast), which has effects of remarkably inhibiting arteriolar basement membrane thickening caused by hypertension etc., or pharmacol. acceptable salts thereof.

IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agent inhibiting hypertensive arteriolar disorder)

RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:900158 CAPLUS
DOCUMENT NUMBER: 135:55773
TITLE: Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat
AUTHOR(S): Pinto, Yigal M.; Pinto-Sietsma, Sara-Joan; Philipp, Tobias; Engler, Sonja; Kossmehl, Peter; Hocher, Berthold; Marquardt, Heike; Sethmann, Svenja; Lauster, Roland; Merker, Hans-Joachim; Paul, Martin

CORPORATE SOURCE: Department of Clinical Pharmacology and Toxicology
Benjamin Franklin Medical Center, Freie Universitat
Berlin, Berlin, 14195, Germany
SOURCE: Hypertension (2000), 36(5), 747-754
CODEN: HPRTDN; ISSN: 0194-911X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Angiotensin II recruits transforming growth factor β1 (TGFβ1) and is related to left ventricular fibrosis. However, it is unclear whether chronic in vivo reduction in left ventricular TGFβ1 expression blunts fibrosis and improves outcome in angiotensin II-dependent hypertension. Four-week-old male hypertensive TGR(mRen2)27 (Ren2) rats received either normal food, low-dose losartan (0.5 mg/kg/d), or tranilast (a nonspecific TGFβ inhibitor; 400 mg/kg/d) for 12 wk and were compared with Sprague-Dawley control rats. The effect of tranilast on survival was evaluated in 34 addnl. untreated homozygous Ren2 rats. Tranilast or low-dose losartan did not lower blood pressure. However, the increase in left ventricular weight (Ren2 vs. SD 3.1 vs. 2.1 mg/g) was significantly blunted by both tranilast (2.7) and losartan (2.7). Both drugs prevented the increase in left ventricular TGFβ1 mRNA and fibronectin mRNA and blunted the increase in hydroxyproline content and the increase in perivascular fibrosis. The perivascular fibrosis score correlated significantly with the level of expression of TGFβ1 ($r = 0.62$). In situ hybridization demonstrated increases in TGFβ1 mRNA, predominantly in perivascular and nonmyocyte areas. Both drugs did not prevent the decrease in systolic or diastolic dP/dt, but tranilast significantly improved the survival of untreated Ren2 rats. In conclusion, TGFβ1 mRNA expression is increased predominantly in nonmyocyte regions in the hypertrophied left ventricle in this angiotensin II-dependent model of hypertension. This increase is probably due to high angiotensin II levels rather than to hypertension. This is the first study to suggest that chronic inhibition of TGFβ1 expression attenuates left ventricular hypertrophy and fibrosis, even without lowering blood pressure.

IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TGF-β1 mRNA reduction in left ventricle attenuates left ventricular fibrosis and improves survival without lowering blood pressure in hypertensive TGR(mRen2)27 rats)

RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:659729 CAPLUS
DOCUMENT NUMBER: 131:295291
TITLE: Effect of tranilast on the retinal vessels

in the hypertensive rat
AUTHOR(S): Honda, Yukie; Aoike, Chiaki
CORPORATE SOURCE: Second Dep. Ophthalmol., Toho Univ. Sch. Med., 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-0044, Japan
SOURCE: Atarashii Ganka (1999), 16(9), 1291-1294
CODEN: ATGAEX; ISSN: 0910-1810
PUBLISHER: Medikaru Ai Shuppan
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB We investigated the effect of tranilast on the retinal vessels in spontaneously hypertensive rats (SHR). Salt loading stroke-prone SHR (SHR-sp) were assigned to either the treated group (dosed with tranilast) or the untreated group. After treatment, computer imaging anal. showed retinal vessel thickness to be significantly inhibited in the treatment group after 8 wk of treatment ($p = 0.008$). This result suggests that tranilast may have an inhibitory effect on early stage hypertensive retinopathy.
IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of tranilast on retinal vessels in hypertensive rat)
RN 53902-12-8 CAPLUS
CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:698915 CAPLUS
DOCUMENT NUMBER: 130:60839
TITLE: Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart
AUTHOR(S): Umemura, Kazuo; Kikuchi, Shinji; Suzuki, Yasuhiro; Nakashima, Mitsuyoshi
CORPORATE SOURCE: Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, 431 - 31, Japan
SOURCE: Japanese Journal of Pharmacology (1998), 78(2), 161-167
CODEN: JJPAAZ; ISSN: 0021-5198
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Tranilast, N-(3,4-dimethoxycinnamoyl)anthranilic acid, a widely used antiallergy drug in Japan, has been shown to inhibit transforming growth factor-β1 release from fibroblasts and reduce collagen synthesis in keloid cells. In the present study, we have investigated the effect of this drug on cardiac hypertrophy in spontaneously hypertensive rats (SHR), with a focus on the cardiac collagen matrix, which is associated with myocardial stiffness. Twenty-four-week-old SHRs and Wistar Kyoto rats (WKYs) were administered tranilast (300 mg/kg) orally once a day for 4 wk. This treatment significantly

suppressed increases in left ventricular collagen concentration (P<0.05) and the
left ventricular weight/body wts. ratios (P<0.05) in SHRs, and tranilast was ineffective on collagen concentration and ventricular weight/body wts. ratios in WKYs. Tranilast did not affect systolic or diastolic blood pressure, end-diastolic left ventricular pressure and heart rate in both SHRs and WKYs, and the agent did not change pos. dp/dt or cardiac output in SHRs. The pressure-volume relation curve was shifted to the left by the drug; the slope (k) of the logarithm of the pressure-volume relation curve was significantly increased (P<0.05) in SHRs. It is concluded that the suppression of increases in cardiac collagen and left ventricular mass by tranilast results in a corresponding prevention of cardiac stiffness as studied in the SHR.

IT 53902-12-8, Tranilast
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart)

RN 53902-12-8 CAPLUS

CN Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>